Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety, tolerability, bioactivity, and dose
response of two different dosages (0.5 mg and 2.0 mg) of ranibizumab (RBZ) in patients with
diabetic macular edema (DME).